Grufity logoGrufity logo

IART

54.00USD+0.31(+0.58%)Market Closed

Integra LifeSciences Holdings Corp

Market Summary

USD54.00+0.31Market Closed
0.58%

IART Stock Price

RSI Chart

Valuation

Market Cap

4.2B

Price/Earnings

24.31

Price/Sales

2.69

Price/Cashflow

16.93

MarketCap/EBT

20.88

Price/Sales

Profitability

EBT Margin

12.87%

Return on Equity

10.03%

Return on Assets

4.54%

Fundamentals

Revenue

Revenue (TTM)

1.6B

Revenue Y/Y

-0.43%

Revenue Q/Q

-3.17%

Earnings

Earnings (TTM)

173.0M

Earnings Y/Y

15.47%

Earnings Q/Q

11.45%

Price Action

52 Week Range

40.6769.95
(Low)(High)

Last 7 days

1.2%

Last 30 days

14.4%

Last 90 days

10.8%

Trailing 12 Months

-20.0%

Financial Health

Current Ratio

3.93

Debt/Equity

0.47

Debt/Cashflow

0.31

Investor Care

Buy Backs (1Y)

1.39%

Diluted EPS (TTM)

2.06

Peers (Alternatives to Integra LifeSciences Holdings)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
183.3B
31.3B
5.22% -15.14%
27.1
5.87
11.35% 14.95%
115.4B
31.1B
-7.32% -29.47%
22.17
3.71
-1.67% 34.08%
86.7B
17.9B
1.82% -7.99%
41.71
4.92
7.67% 29.32%
86.3B
6.1B
9.71% -21.89%
62.6
14.1
11.47% -18.42%
43.9B
5.4B
-11.99% -33.30%
30.09
8.18
5.29% -1.25%
MID-CAP
6.7B
998.4M
7.06% 6.92%
44.21
6.87
6.04% -19.01%
6.4B
806.4M
10.81% -24.63%
-331.15
7.96
20.10% -221.96%
4.2B
1.6B
14.38% -19.95%
24.31
2.69
2.60% -20.07%
3.9B
380.1M
-15.13% 7.13%
-29.57
10.69
18.85% -63.58%
3.4B
279.3M
-17.23% -42.23%
101.81
13.07
28.45% 65.13%
SMALL-CAP
994.0M
154.8M
-3.42% -51.74%
-10.57
6.72
60.29% -2309.58%
722.1M
199.9M
32.65% -44.00%
-462.32
3.61
43.88% -138.55%
104.4M
13.1M
-19.27% -82.50%
-1.64
7.86
13.64% 4.49%
11.1M
3.2M
-11.02% -84.06%
-0.99
3.82
22.61% -47.81%

Financials for Integra LifeSciences Holdings

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue-0.1%1,5651,5671,5591,5421,526
  S&GA Expenses-1.9%627639641637638
Earnings Before Taxes4.1%201193187215202
Net Income4.0%173166157169216
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets1.4%3,8073,7533,6723,7823,774
  Current Assets5.2%1,1961,1371,0661,1541,104
    Cash Equivalents14.5%512447407513470
  Inventory-2.9%311320328317327
  Net PPE-0.6%301302309312294
  Goodwill-1.3%9789901,0091,0131,012
Liabilities-0.4%2,0832,0922,0572,0982,143
  Current Liabilities3.0%304296316340333
  Long Term Debt-1.4%810821833855-
Shareholder's Equity3.8%1,7241,6611,6151,6851,632
  Retained Earnings6.4%826776731699653
  Additional Paid-In Capital-0.5%1,2601,2671,2651,259-
Shares Outstanding-0.6%838485--
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-5.5%248263288312323
  Share Based Compensation4.5%2827363635
Cashflow From Investing42.7%-31.24-54.52-57.94-161.44-169.88
Cashflow From Financing-6.5%-153.73-144.35-228.68-98.23-77.53
  Buy Backs0%12512512500
* denotes actual numbers (not divided by Millions)

Risks

What is the probability of a big loss on IART?

56.9%


Probability that Integra LifeSciences Holdings stock will be more than 20% underwater in next one year

41.9%


Probability that Integra LifeSciences Holdings stock will be more than 30% underwater in next one year.

8.5%


Probability that Integra LifeSciences Holdings stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does IART drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Integra LifeSciences Holdings was unfortunately bought at previous high price.

Returns

Cumulative Returns on IART

12.0%


10-Year Cumulative Returns

8.1%


7-Year Cumulative Returns

2.2%


5-Year Cumulative Returns

-4.0%


3-Year Cumulative Returns

What are the long-term rolling returns for IART?

FIve years rolling returns for Integra LifeSciences Holdings.

Which funds bought or sold IART recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
NEW
-
4,268,000
4,268,000
0.05%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
ADDED
2.13
-1,022,000
4,109,000
0.01%
2022-11-21
FourThought Financial, LLC
ADDED
106.39
7,000
19,000
-%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
REDUCED
-0.16
-57,000
205,000
-%
2022-11-16
Front Row Advisors LLC
NEW
-
4,000
4,000
-%
2022-11-16
Neo Ivy Capital Management
NEW
-
30,000
30,000
0.08%
2022-11-16
Retirement Systems of Alabama
ADDED
0.98
-1,060,000
4,029,000
0.02%
2022-11-15
BURNEY CO/
SOLD OFF
-100
-220,000
-
-%
2022-11-15
COOKE & BIELER LP
ADDED
9.61
-18,953,000
115,764,000
1.24%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
SOLD OFF
-
-
-
-%

1–10 of 39

Latest Funds Activity

Are funds buying IART calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own IART

Integra LifeSciences Holdings News

Yahoo Finance

ClearBridge Investments’ Major Performance Detractor: Azenta (AZTA).6 hours ago

IART Fair Value

Recent SEC filings of Integra LifeSciences Holdings

View All Filings
Date Filed Form Type Document
Nov 03, 2022
4
Insider Trading
Oct 26, 2022
8-K
Current Report
Oct 26, 2022
10-Q
Quarterly Report
Oct 13, 2022
4
Insider Trading
Oct 12, 2022
3
Insider Trading
Oct 11, 2022
SC 13G/A
Major Ownership Report
Sep 23, 2022
8-K
Current Report
Aug 29, 2022
8-K
Current Report
Aug 24, 2022
8-K
Current Report

Latest Insider Trading transactions for IART

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-08-10
Evoli Lisa
SOLD
-65,019.6
55.8108
-1,165
Executive Vice President &CHRO
2022-08-05
Murphy Raymond G.
SOLD
-446,266
55.7833
-8,000
-
2022-08-03
Evoli Lisa
SOLD (Taxes)
-16,214.6
55.34
-293
Executive Vice President &CHRO
2022-08-02
Mosebrook Jeffrey
SOLD
-24,810.7
56.775
-437
SVP, Fin & Princ Acct Officer
2022-08-01
McBreen Michael J.
SOLD (Taxes)
-34,065.1
56.87
-599
EVP & President, CSS
2022-08-01
Evoli Lisa
SOLD (Taxes)
-25,932.7
56.87
-456
Executive Vice President &CHRO
2022-07-27
Lo Renee Wonlai
ACQUIRED
-
-
2,969
-
2022-07-01
Anderson Carrie L
SOLD (Taxes)
-243,375
55
-4,425
Executive Vice President & CFO
2022-07-01
Coleman Glenn
SOLD (Taxes)
-366,630
55
-6,666
Executive Vice President & COO
2022-06-15
Evoli Lisa
SOLD
-50,337
55.93
-900
Executive Vice President &CHRO

1–10 of 50

Jan D. de Witte
3800
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

IART Income Statement

2022-09-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (UNAUDITED) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]    
Total revenue, net$ 385,191$ 386,861$ 1,159,644$ 1,136,924
Costs and expenses:    
Cost of goods sold148,445144,468439,418441,558
Research and development24,73625,83174,41068,326
Selling, general and administrative143,820156,010464,397475,195
Intangible asset amortization3,1414,11310,33912,838
Total costs and expenses320,142330,422988,564997,917
Operating income65,04956,439171,080139,007
Interest income3,2641,7866,6065,298
Interest expense(12,809)(12,192)(36,700)(38,270)
Gain (loss) from the sale of businesses644(230)64441,967
Other income, net2,6484,9858,05614,888
Income before income taxes58,79650,788149,686162,890
Provision for income taxes8,8817,55922,08239,199
Net income$ 49,915$ 43,229$ 127,604$ 123,691
Net income per share    
Basic (in dollars per share)$ 0.60$ 0.51$ 1.54$ 1.46
Diluted (in dollars per share)$ 0.60$ 0.51$ 1.53$ 1.45
Weighted average common shares outstanding (See Note 13):    
Basic (in shares)83,04284,75482,95584,647
Diluted (in shares)83,39985,44783,47685,391
Comprehensive income (See Note 14)$ 55,691$ 46,417$ 165,320$ 150,975

IART Balance Sheet

2022-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 511,937$ 513,448
Trade accounts receivable, net of allowances of $3,958 and $4,735248,268231,831
Inventories, net311,060317,386
Prepaid expenses and other current assets123,35791,051
Assets held for sale1,8310
Total current assets1,196,4531,153,716
Property, plant and equipment, net300,729311,703
Right of use asset - operating leases148,27084,543
Intangible assets, net1,054,0351,145,573
Goodwill977,8601,013,458
Deferred tax assets, net51,76856,950
Other assets77,89816,440
Total assets3,807,0133,782,383
Current liabilities:  
Current portion of borrowings under senior credit facility56,25045,000
Current portion of lease liability - operating leases13,48814,775
Accounts payable, trade80,73261,837
Contract liabilities6,3645,295
Accrued compensation68,62692,656
Accrued expenses and other current liabilities78,992120,458
Total current liabilities304,452340,021
Long-term borrowings under senior credit facility814,530824,257
Long-term borrowings under securitization facility106,000112,500
Long-term convertible securities566,612564,426
Lease liability - operating leases157,53390,329
Deferred tax liabilities69,74345,788
Other liabilities63,729120,258
Total liabilities2,082,5992,097,579
Stockholders’ equity:  
Preferred stock; no par value; 15,000 authorized shares; none outstanding00
Common stock; $0.01 par value; 240,000 authorized shares; 90,341 and 89,600 issued at September 30, 2022 and December 31, 2021, respectively903896
Additional paid-in capital1,267,6411,264,943
Treasury stock, at cost; 6,823 shares and 4,899 shares at September 30, 2022 and December 31, 2021, respectively(362,863)(234,448)
Accumulated other comprehensive loss(7,439)(45,155)
Retained earnings826,172698,568
Total stockholders’ equity1,724,4141,684,804
Total liabilities and stockholders’ equity$ 3,807,013$ 3,782,383